Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
Cephalalgia
; 21(1): 66-70, 2001 Feb.
Article
in En
| MEDLINE
| ID: mdl-11298666
ABSTRACT
The prophylactic action of cyclandelate was investigated in a multicentre, randomized, placebo-controlled, parallel group study. A 4-week baseline period was followed by a 4-week placebo phase and a 16-week treatment period with either 1600 mg cyclandelate or placebo. Patients (n = 251) with two to six migraine attacks/month were randomized. Neither the primary study endpoint (reduction of migraine days from baseline to the last 28 days) nor most of the secondary endpoints (reduction in the number of migraine attacks, severity or duration of attacks, frequency of autonomic disturbances, medication for treatment of attacks) showed a difference between cyclandelate and placebo. Cyclandelate, however, was superior to placebo in a global impression of efficacy rated by the patients and the treating physicians. Both treatments were well tolerated. In conclusion, cyclandelate was not superior to placebo in the prophylaxis of migraine with regard to parameters usually used in migraine prophylaxis trials.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vasodilator Agents
/
Cyclandelate
/
Migraine Disorders
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cephalalgia
Year:
2001
Document type:
Article
Affiliation country:
Germany